Bayrakçi Sinem, Şahin Ahmet, Bayrakçi Onur, Aslan Selda
Department of Intensive Care Unit, Gaziantep City Hospital, Gaziantep, Turkey.
Dr. Ersin Arslan Training and Research Hospital Infectious Diseases and Clinical Microbiology Department, Gaziantep, Turkey.
Medicine (Baltimore). 2025 Jun 27;104(26):e42946. doi: 10.1097/MD.0000000000042946.
Ventilator-associated pneumonia (VAP) is one of the most common and serious infections in hospitalized patients. VAP is associated with worse outcomes and significant morbidity and mortality worldwide. Our primary goal in this study was to identify the VAP pathogen with its distribution characteristics, clarify risk factors, prognosis, and outcomes, and help reduce associated morbidity and mortality. This retrospective observational study was conducted between June 2019 and June 2022 in 3 general intensive care units of a training and research hospital. Data on demographic, clinical and laboratory parameters were collected retrospectively from medical cards and electronic records. A total of 204 patients were diagnosed with VAP caused by Gram-negative microorganisms. Chronic renal failure (RF) and neurological diseases were significantly associated with mortality (P = .01, P = .023). The duration of mechanical ventilation before VAP and the duration of mechanical ventilation were significantly longer in survivors compared to non-survivors. The number of patients with early VAP was significantly higher, and the days of VAP were shorter in the non-survivors compared to the survivors (P = .006, P = .016). The number of VAP episodes (P = .0001), the presence of RF, acute respiratory distress syndrome, bacteremia, and sepsis before VAP (<48 hours) were associated with mortality. Intensive care unit and the length of hospital stay were significantly shorter in non-survivors than in survivors (P = .0003, P = .0001). Administration of monotherapy, inadequate empirical antibiotic therapy, inadequate antibiotic therapy (P = .004, P = .002, and P = .0006), persistence of the pathogen (P = .0001), C-reactive protein and procalcitonin levels (P = .002, P = .041) were associated with mortality. The presence of neurological diseases and RF was associated with a greater likelihood of mortality in patients with VAP. As risk factors, early-onset VAP, presence of RF-acute respiratory distress syndrome-bacteremia-sepsis 48 hours before VAP, organ failure, need for hemodialysis, shock and the persistence of the pathogen increased the risk of mortality.
呼吸机相关性肺炎(VAP)是住院患者中最常见且最严重的感染之一。在全球范围内,VAP与更差的预后以及显著的发病率和死亡率相关。本研究的主要目标是确定VAP病原体及其分布特征,阐明危险因素、预后和结局,并帮助降低相关的发病率和死亡率。这项回顾性观察性研究于2019年6月至2022年6月在一家培训和研究医院的3个综合重症监护病房进行。人口统计学、临床和实验室参数数据通过病历和电子记录进行回顾性收集。共有204例患者被诊断为革兰氏阴性微生物引起的VAP。慢性肾衰竭(RF)和神经系统疾病与死亡率显著相关(P = 0.01,P = 0.023)。与非幸存者相比,VAP发生前机械通气的持续时间以及机械通气的总持续时间在幸存者中显著更长。非幸存者中早期VAP患者的数量显著更多,且VAP持续天数比幸存者更短(P = 0.006,P = 0.016)。VAP发作次数(P = 0.0001)、RF的存在、急性呼吸窘迫综合征、菌血症以及VAP发作前(<48小时)的脓毒症与死亡率相关。非幸存者的重症监护病房住院时间和住院总时长显著短于幸存者(P = 0.0003,P = 0.0001)。单一疗法的使用、经验性抗生素治疗不足、抗生素治疗不足(P = 0.004,P = 0.002,P = 0.0006)、病原体持续存在(P = 0.0001)、C反应蛋白和降钙素原水平(P = 0.002,P = 0.041)与死亡率相关。神经系统疾病和RF的存在使VAP患者死亡的可能性更大。作为危险因素,早发性VAP、VAP发作前48小时存在RF - 急性呼吸窘迫综合征 - 菌血症 - 脓毒症、器官衰竭、需要血液透析、休克以及病原体持续存在均增加了死亡风险。